All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.

The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
  TRANSLATE

The MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

Jean-Jacques KiladjianChair

Jean-Jacques Kiladjian is a Professor of Clinical Pharmacology at Université Paris Cité, Paris, FR, and a Consultant Hematologist and Head of the Clinical Investigation Center of Hôpital Saint-Louis, Paris, FR. Professor Kiladjian’s work focuses on clinical research and the development of novel therapeutics for the treatment of patients with myeloproliferative neoplasms (MPN) and myelodysplastic syndromes. 

Professor Kiladjian is an active member of many societies, including the European Hematology Association, for which he is co-chair of the Scientific Working Group on MPN. He is also a member of the American Society of Hematology, as well as the European LeukemiaNet, for which he is secretary of the MPN Working Group, and president of the French Intergroup of Myeloproliferative neoplasms.  

|||